Anavex Life Sciences Announces Board Refresh, Nominates Two New Independent Directors

ANAVEX LIFE SCIENCES CORP.

Nominates Gautam Patel and Dr. Adrian Senderowicz as new independent director candidates for 2026 Annual Meeting.
Current board members Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Dr. Claus van der Velden also stand for reelection.
Urges stockholders to reject PVG Asset Management and Patrick Adams' attempt to replace entire board; PVG owns only 0.35% of shares.
Former CEO Christopher Missling terminated for cause and not renominated; Dr. Terrie Kellmeyer appointed interim CEO.
Company focuses on blarcamesine for Alzheimer's, Rett syndrome, Fragile X; strong cash runway, no long-term debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.